The overarching goal of the Clinical Core is to characterize the behavioral, cognitive, motor, neuroimaging, proteomic and genetic features of ADRC subjects in novel, multidisciplinary ways, and facilitate enrollment of subjects in studies of normal and abnormal aging.
The specific aims of the Clinical Core are to 1) Recruit, evaluate, and longitudinally follow cohorts of normal elderly (n=300), patients with mild cognitive impairment (MCI;n=150), mild AD (n=100), frontotemporal lobar degeneration (FTLD;n=75), HIV (n=50), amyotrophic lateral sclerosis (ALS;n=20), corticobasal degeneration and progressive supranuclear palsy (CBD/PSP; n=25), and Creutzfeldt-Jakob disease (CJD;n=20), and members of families with known mutations in genes that predispose them to FTLD;2) Work with the Education Core to recruit, evaluate, and longitudinally follow Chinese-American (n=100) and Latino (n=50) patients and controls;3) Provide clinical data and well characterized subjects for research on aging and neurodegenerative disease;and 4) Obtain biological samples for genomic and proteomic research, and contributing novel cohorts, including Chinese-American and FTLD patients, to the National Cell Repository for AD (NCRAD). All subjects will be evaluated using the UDS plus several neurological, cognitive, and personality measures specific to UCSF to better understand the heterogeneity of and overlap between dementias, improve our ability to capture the very earliest signs of neurodegeneration, study the transition from normal aging to MCI, and facilitate interventions.
The prevalence of dementing disorders will soon reach epidemic proportions in the United States. By recruiting and assessing a broad range of patients and elderly controls, the Clinical Core of this ADRC plays a central role in this ADRC's ability to promote the interventional, translational, and biological research in dementias necessary to develop new treatments and optimize patient care.
|Bernier, Patrick J; Gourdeau, Christian; Carmichael, Pierre-Hugues et al. (2017) Validation and diagnostic accuracy of predictive curves for age-associated longitudinal cognitive decline in older adults. CMAJ 189:E1472-E1480|
|Ranasinghe, Kamalini G; Hinkley, Leighton B; Beagle, Alexander J et al. (2017) Distinct spatiotemporal patterns of neuronal functional connectivity in primary progressive aphasia variants. Brain 140:2737-2751|
|Sposato, Luciano A; Ruíz Vargas, Estefanía; Riccio, Patricia M et al. (2017) Milder Alzheimer's disease pathology in heart failure and atrial fibrillation. Alzheimers Dement 13:770-777|
|Moga, Daniela C; Abner, Erin L; Wu, Qishan et al. (2017) Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y) 3:139-148|
|Sturm, Virginia E; Perry, David C; Wood, Kristie et al. (2017) Prosocial deficits in behavioral variant frontotemporal dementia relate to reward network atrophy. Brain Behav 7:e00807|
|Scherling, Carole S; Zakrzewski, Jessica; Datta, Samir et al. (2017) Mistakes, Too Few to Mention? Impaired Self-conscious Emotional Processing of Errors in the Behavioral Variant of Frontotemporal Dementia. Front Behav Neurosci 11:189|
|Sennik, Simrin; Schweizer, Tom A; Fischer, Corinne E et al. (2017) Risk Factors and Pathological Substrates Associated with Agitation/Aggression in Alzheimer's Disease: A Preliminary Study using NACC Data. J Alzheimers Dis 55:1519-1528|
|Fernández-Fournier, Mireya; Perry, David C; Tartaglia, Maria Carmela et al. (2017) Precipitous Deterioration of Motor Function, Cognition, and Behavior. JAMA Neurol 74:591-596|
|Neu, Scott C; Pa, Judy; Kukull, Walter et al. (2017) Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol 74:1178-1189|
|Burke, Shanna L; O'Driscoll, Janice; Alcide, Amary et al. (2017) Moderating risk of Alzheimer's disease through the use of anxiolytic agents. Int J Geriatr Psychiatry 32:1312-1321|
Showing the most recent 10 out of 501 publications